Aggressive Surgical Approach to the Management of Neuroendocrine Tumors: A Report of 1,000 Surgical Cytoreductions by a Single Institution

Woltering, Eugene A.; Voros, Brianne A.; Beyer, David T.; Wang, Yi-Zarn; Thiagarajan, Ramcharan; Ryan, Pamela; Wright, A.; Ramirez, Robert A.; Ricks, M. Jennifer; Boudreaux, J. Philip

doi:10.1016/j.jamcollsurg.2016.12.032

Cited by 62 publications

(63 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It is estimated that up to 40% of cases may retain the ileocecal valve (14). Boudreaux et al conducted several studies assessing the role of stains such as isosulfan blue or methylene blue in the mapping of lymphatic drainage (9,14,30). If the lymphatic vessels of the ileocecal valve are colored, then there is a high risk of metastasis and right hemicolectomy should be performed.…”

Section: Surgical Proceduresmentioning

confidence: 99%

“…According to current European Neuroendocrine Tumor Society guidelines (42), resection of liver metastases should be considered when R0 resection of grade 1/2 metastatic tumor is feasible with acceptable predicted morbidity (~30%) and mortality <5%, in the absence of right heart failure or extra-abdominal metastases and diffuse peritoneal carcinomatosis; however, the latter is debatable in terms of cytoreductive surgery (9,16,43).…”

Section: Liver Metastasesmentioning

confidence: 99%

“…It has been supported that >70% or even 90% of the metastatic burden in liver should be resected for obtaining clinical benefit (36). Recent studies have shown that debulking surgery with a cut-off at 70% has resulted in 5-year OS of 75% (9,36). Thus, it may be a feasible option in patients with advanced-staged disease.…”

Section: Liver Metastasesmentioning

confidence: 99%

“…Lack of symptomatic disease is by no means a contradiction for surgery (30). Early surgical intervention may prevent an emergency surgery that would be accompanied by high morbidity and mortality risk (9,30). More than 80% of these patients have multifocal disease and one-third of them have stage III disease.…”

Section: Asymptomatic Primary Tumormentioning

confidence: 99%

“…In this setting, surgery aims to reduce the disease burden in order to improve survival. Patients with operable disease have better prognosis than those with inoperable, even in advanced stages (9,10). Approximately 80% of disease-related deaths are due to liver insufficiency and 16% due to bowel obstruction; therefore, surgical intervention may help improve survival and quality of life (11).…”

mentioning

confidence: 99%

See 4 more Smart Citations

Update on Surgical Management of Small Bowel Neuroendocrine Tumors

Moris

Ntanasis‐Stathopoulos

Tsilimigras

et al. 2018

View full text Add to dashboard Cite

show abstract

Section: Surgical Proceduresmentioning

confidence: 99%

Section: Liver Metastasesmentioning

confidence: 99%

Section: Liver Metastasesmentioning

confidence: 99%

Section: Asymptomatic Primary Tumormentioning

confidence: 99%

mentioning

confidence: 99%

See 3 more Smart Citations

Update on Surgical Management of Small Bowel Neuroendocrine Tumors

Moris

Ntanasis‐Stathopoulos

Tsilimigras

et al. 2018

View full text Add to dashboard Cite

show abstract

Surgical treatment for gastrointestinal neuroendocrine tumors

Eto

Yoshida

Iwagami

et al. 2020

Annals of Gastroent Surgery

View full text Add to dashboard Cite

Neuroendocrine tumors (NETs) are rare neoplasms, with an estimated annual incidence of 6.9/100 000. They arise from cells of the diffuse endocrine system, which are mainly dispersed throughout the gastrointestinal (GI), pancreatic, and respiratory tracts. The incidence of GI‐NETs has recently begun to show a steady increase. According to the Surveillance, Epidemiology, and End Results database, 53% of patients with NETs present with localized disease, 20% with locoregional disease, and 27% with distant metastases at the time of diagnosis. Surgery is the mainstay for the treatment of locoregional GI‐NETs. Endoscopic resection is an option for well‐differentiated early GI‐NETs, which are thought to very rarely metastasize to lymph nodes. A lesion that is technically difficult to resect via endoscopy is an indication for local resection (partial resection without lymph node dissection). GI‐NETs with possible lymph node metastasis is an indication for enterectomy with lymph node dissection. For NETs with metastatic lesions, cytoreduction surgery can control hormonal hypersecretion and alleviate symptoms; therefore, cytoreduction surgery is recommended. The indications for surgery vary and are based on the organ where the NET arose; therefore, an understanding of the patient's clinical state and individualized treatment that is based on the characteristics of the patient's GI‐NET is needed. This review summarizes surgical treatments of GI‐NETs in each organ.

show abstract

The Chicago Consensus on peritoneal surface malignancies: Management of neuroendocrine tumors

Schuitevoerder¹,

Plana²,

Izquierdo³

et al. 2020

Cancer

View full text Add to dashboard Cite

The Chicago Consensus Working Group provides multidisciplinary recommendations for the management of neuroendocrine tumors specifically related to the management of peritoneal surface malignancy. These guidelines are developed with input from leading experts, including surgical oncologists, medical oncologists, pathologists, radiologists, palliative care physicians, and pharmacists. These guidelines recognize and address the emerging need for increased awareness in the appropriate management of peritoneal surface disease. They are not intended to replace the quest for higher levels of evidence. Cancer 2020;126:2561-2565.

show abstract

Aggressive Surgical Approach to the Management of Neuroendocrine Tumors: A Report of 1,000 Surgical Cytoreductions by a Single Institution

Cited by 62 publications

References 33 publications

Update on Surgical Management of Small Bowel Neuroendocrine Tumors

Update on Surgical Management of Small Bowel Neuroendocrine Tumors

Surgical treatment for gastrointestinal neuroendocrine tumors

The Chicago Consensus on peritoneal surface malignancies: Management of neuroendocrine tumors

Contact Info

Product

Resources

About